In conclusion, the 2903 bp deletion polymorphism of BIM is associated with poor response to EGFR-TKIs, primarily the first-generation inhibitors, in EGFR-mutant NSCLC patients. The gene discussed is BCL2L11; the disease is non-small cell lung carcinoma.